ProKidney Reports 78 Percent Gain in Q2

ProKidney (NASDAQ:PROK), a biopharmaceutical company developing cell therapies for chronic kidney disease (CKD), released its second quarter results on August 12, 2025. The main focus of the release was encouraging clinical updates for its lead product rilparencel, especially from the Phase 2 REGEN-007 study, and a regulatory milestone with the U.S. Food and Drug Administration (FDA) accepting eGFR slope as an accelerated approval endpoint. The company reported a net loss per share of $0.13 (GAAP) for the quarter. This was better than the $0.14 loss anticipated. Revenue (GAAP) was $221,000, an unexpected result, though still minimal and not core to operations. Overall, the quarter showed prudent cost management, ongoing R&D investment, and operational execution, supported by a solid liquidity position. Source: Analyst estimates for the quarter provided by FactSet. ProKidney develops autologous cell therapies designed to slow or halt disease progression for patients with chronic kidney disease, especially those with diabetes-driven CKD. Its core approach centers on rilparencel, a therapy that uses cells from a patient’s own kidney tissue to help preserve kidney function.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool